Global Investing Roundups

Oil Continues Slide; FDA Blocks Ranbaxy, Best Buy Profit Declines; Bristol-Myers Bid Uncertain; Pandit’s Reassuring Memo; GM Showcases the Volt; Adobe Beats the Street; Constellation Plunges on Debt Worries

  • Oil prices extended their decline yesterday (Tuesday), falling $10 a barrel in a dramatic, two-day slide as the outlook for U.S., as well as global, energy demand grew weaker. Light, sweet crude for October delivery fell $4.56 to settle at $91.15 a barrel on the New York Mercantile Exchange, after earlier falling as low as $90.51 – the lowest level since Feb. 8.
  • The Food and Drug Administration is closing U.S. borders to more than 30 generic drugs made by India's Ranbaxy Laboratories Ltd. (OTC: RBXLY), citing poor quality in two of the company’s factories, The Associated Press reported.  However, Ranbaxy can continue selling medicines made at any of its other factories.
  • Best Buy Co. (BBY) said yesterday (Tuesday) that its second-quarter profit fell 19%, to $202 million, despite a 12% jump in revenue.  Same-store sales jumped 4.2% and total revenue came in at $9.8 billion. A sluggish U.S. economy will continue to challenge the retail giant the second half of the year.
  • Bristol-Myers Squibb Co. (BMY) said yesterday (Tuesday) that it might drop its $4.5 billion offer for the 83% of ImClone Systems Inc. (IMCL) it doesn't already own. "There are situations in which we are willing, and we've disclosed that, we're willing to walk away," Jean-Marc Huet, Bristol’s Chief Financial Officer, said response to a question at a pharmaceutical investors conference, The Associated Press reported.